News & Updates

In the CONFIDENT trial, convalescent plasma (CCP) conferred a mortality benefit for patients with COVID-19-induced acute respiratory distress syndrome (ARDS) who were on invasive mechanical ventilation (IMV).

In the phase III BOREAS trial, the monoclonal antibody dupilumab conferred multiple benefits for individuals with chronic obstructive pulmonary disease (COPD) and type 2 (T2) inflammation.

Multiple risk factors for pulmonary hypertension such as age, sex, and weight, among others, do not appear to influence the severity of interstitial lung disease (ILD), according to a recent study presented at APSR 2023.

Simply developing evidence-based recommendations is not enough to improve asthma care. These recommendations should also be disseminated and implemented at national and local levels, then integrated into routine clinical practice to have a positive effect on patient outcomes, according to an expert.

In patients with poor asthma control, switching from fluticasone propionate (FP) monotherapy to inhaled corticosteroid (ICS) plus a long-acting beta-agonist (LABA) combination therapy may help improve symptom control and reduce the use of reliever or rescue medications, according to a study.

Results of nintedanib use in patients with early-stage idiopathic pulmonary fibrosis (IPF) show a stable change in forced vital capacity (FVC) and a gradual decline in diffusing capacity of the lungs for carbon monoxide (DLCO) at week 52, according to an ongoing study presented at APSR 2023. In addition, treatment discontinuation is comparable to that in previous clinical trials.

The presence of asthma education and Asthma Control Test (ACT) may prevent exacerbations or at least delay the onset of severe exacerbations, suggests a Singapore study.

A study presented at ACAAI 2023 demonstrated the potential of simple home remedies such as gargling and nasal rinsing with saltwater in cutting COVID-19 hospitalization rates.